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Resting  T  cells spontaneously  adhere  in  a selective manner  to potent  accessory cells,  such  as 
dendritic  cells (DC)  and lymphoblastoid B  blasts (LCL).  Here we demonstrate  that leukosialin 
(CD43)  and major histocompatibility complex class I molecules  (MHC-I) might play a critical 
role in this process. T  cell conjugate formation with monocyte-derived DC (md-DC) and LCL 
could be strongly inhibited by either preincubating T  cells with Fab fragments of CD43 mono- 
clonal antibody  (mAb)  6F5  or by preincubating  md-DC  or LCL with MHC-I  mAb W6/32. 
Intact CD43 mAb 6F5, in contrast to monovalent Fab fragments, enhanced T  cell adhesiveness 
by transactivating CD2 binding  to CD58  molecules.  Interestingly,  induction  of this proadhe- 
sive signal via CD43  with intact 6F5 mAb was found to revert mAb W6/32-mediated  inhibi- 
tion  of T  cell  conjugate  formation.  These  observations  indicated  that  CD43  cross-linkage 
mimics and monovalent mAb 6F5 inhibits interaction ofT cell CD43 with a stimulatory ligand 
on  opposing  cells,  presumably MHC-I.  For  the  demonstration  of direct  physical interaction 
between CD43  on T  cells and MHC-I-coated beads it was necessary, however, to ligate CD2 
on T  cells with a stimulatory pair ofCD2  mAbs (VIT13 plus TS2/18).  This suggests that CD2 
ligation crosswise upregulates CD43 binding avidity for MHC-I  and that both adhesion mole- 
cule pairs (CD43/MHC-I  and CD2/CD58)  act in concert to induce and mediate T  cell conju- 
gate formation with certain cell types. 
p physical contact formation with other cells is an essential 
feature of T  lymphocytes.  It is required  for the induc- 
tion of antigen-specific T  cell activation by APC  (1-4) and 
represents an essential step in most effector functions medi- 
ated by activated T  lymphocytes (5-9). 
Antigen-induced  T  cell activation requires the formation 
of intimate contact between T  ceils and APC. This binding 
process can be divided into two events. The first step in this 
heteroadhesion  process  seems  to  be  antigen  independent 
and to precede  antigen/MHC  recognition  by TC1L  (2,  5, 
10-13).  This ininal,  randomly occurring interaction  allows 
T  cells to screen the surface of an opposing cell for the ex- 
pression  of appropriate  TCR  ligands.  Ligation  of TCP, 
molecules  induces  subsequent  activation  of T  cell  mem- 
brane adhesion molecules  (14,  15), which further stabilizes 
conjugate formation between T  cells and target cells or APC. 
Resting T  cells are much more selective than activated 
T  cells in their capacity to physically interact and form sta- 
ble  conjugates  with  other  cells  (1,  4-6,  9,  16).  This  can 
possibly be  explained  by the  observation  that  activated  T 
cells a priori express high-avidity adhesion molecules, whereas 
the majority of adhesion molecules on resting T  cells are in a 
low-avidity-binding  state  (17,  18).  Yet,  resting  T  cells  can 
spontaneously  form  stable  conjugates  with  certain  cell 
types. This is particularly true for potent APC such as den- 
dritic cells (DC) I and activated B blasts (1, 3, 6, 13,  19-21). 
In  contrast,  other  leukocytes  such  as  monocytes/macro- 
phages (1, 22),  resting B  cells (1, 3,  6, 20),  or granulocytes 
(9)  do not spontaneously bind resting T  cells. 
Several adhesion molecule pairs on APC and T  cells, re- 
spectively, have been identified that can contribute  to such 
physical contact and conjugate formation. Among them are 
the adhesion molecule pairs CD2  (LFA-2)/CD58  (LFA-3), 
LFA-1  (CD11a/CD18)/ICAM-1,  2,  3,  and  CD28/B7 
(CD80)  (4,  12,  13,  21,  23,  24).  However,  none  of them 
can  fully  explain  the  observed  exquisite  selectivity  in  the 
binding behavior of resting T  cells to certain APC. 
In an attempt to further analyze the molecular basis of the 
spontaneous adhesion of resting T  cells to DC and B blasts, 
tAbbreviations used in this paper. [32m, [32-mlcroglobulln; CB, cord blood; 
DC, dendnnc  cells; EBV-LCL, EBV-transformed lymphoblastmd B cell 
line; md-DC, monocyte-denved  DC; MHC-I, MHC class I molecules; 
O-SGP,  O-slaloglycoprotease; PB,  peripheral blood;  rh.  recombinant 
human 
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cules potentially involved in this adhesion process. We could 
indeed  demonstrate  a  new,  as  yet  unreported  adhesion 
pathway.  It  involves leukosialin (CD43)  on  T  cells  and 
MHC  class I molecules (MHC-I) on DC and B  blasts, re- 
spectively.  Interaction between  these  two  molecules can 
promote T  cell binding to such cells m  two ways: via direct 
CD43/MHC-I  binding and via transduction of proadhe- 
sive  signals  leading  to  enhanced  CD2-mediated  CD58 
binding. 
Materials  and Methods 
Media, Reagents, and Chen~icals.  The cell culture medium RPMI 
1640  (Gibco Ltd.,  Paisley,  Scotland)  was  supplemented with 2 
mM t-glutamine, 10% FCS, 100 U/ml penicillin, and 100 }xg/ml 
streptomycin, except for EBV-transformed lymphoblastoid B cell 
lines (LCL) HB654-SN and XX224, which were cultured in se- 
rum-free DMEM/F-12 medium (catalog  no. B-1004-BB; Hy- 
clone,  Logan,  UT)  to  which  insulin-transferrin-sodium  selemt 
supplement (catalog no. 1074547; Boehringer-Mannheim, Penz- 
berg,  Germany), 0.002%  human serum albumin (Behring Insti- 
tute, Vienna, Austria) and further 50 txg/ml of L-cystein (Merk, 
Darmstadt,  Germany) and 30 Ixg/ml of L-serin and L-methlonin 
(Fluka Chemle, Vienna, Austria) was added. 
Recombinant human (rh) GM-CSF and rhlL-4 were kindly 
provided by Sandoz Research Insntute (Vienna, Austna). rhTNF-c~ 
was a kind gift from G. R. Adolf (Ernst Boehrlnger Instltut ffir 
Arzneimittelforschung,  Vienna,  Austria).  O-sialoglycoprotease 
(O-SGP) from Pasteurella haemolytica was obtained from D. Suth- 
erland (Oncology Research,  Toronto Hospital,  Toronto,  Can- 
ada). Neurarmmdase from Vibrio cholerae  was purchased from Behrlng 
Behringwelke AG, (Marburg,  Germany). 
Purified  ~2-microglobulin  ([32m), cytochalasin  B,  EDTA, 
neuraminic acid (type VIII), sodium metapenodate,  sodium arsen- 
lte solunon, thlobarbltunc acid, cyclohexanone, and NaF were pur- 
chased  from  Sigma  Chemle  GmbH  (Delsenhofen,  Germany). 
Formaldehyde was obtained from Polysciences Inc. (Warrmgton, 
PA).  In some  experiments, either APC  or  T  cells  were  pre- 
treated with 10 mM EDTA for 30 nun at room temperature and 
washed afterwards with calclum/magnesmm-free PBS. Cytochalasin 
B (5 b~g/ml) or NaF (30 mM) premcubation was carried  out at 
37°C for 30 nun. Fixation of cells, with precooled 1% formalde- 
hyde in PBS, was performed for 20 rain strictly at 0°C before wash- 
ing with PBS. 
Antibodies.  Antibodies were used at a final concentration of 
10  Ixg/ml.  The following murine mAbs were generated in our 
laboratory:  VIAP  (calf intestine alkaline  phosphatase  specific), 
VIT13 (CD2R), VIT3 (CD3),  VIT4 (CD4),  5D7 (CD5),  VIT8 
(CD8),  VIMI3  (CD14),  6F5  and  10G4  (CD43),  6B6  (CD44), 
VIT200 and 562  (CD45),  VIM3c (CD97),  TA9 (CD99),  LA-45 
(MHC class I free o~ chain), AAA1 (M6 antigen). The CD2 mAb 
TS2/18-, CD11a mAb TS1/22-, HLA-DR mAb L243-, MHC 
class  I  mAb  W6/32-,  CD58  mAb  TS2/9-,  and  ~2  m  mAb 
BBM.l-producing hybridomas  were  obtained from  American 
Type Culture Collection (Rockvllle, MD). The following mAbs 
were kindly provided: CD14 mAb MEM18 and CD45R0 mAb 
UCHLI  were  from  An  der  Grub  (Bio  Forschungs  GmbH, 
Kaumberg, Austria);  CD26  mAb A24  (134-2C2)  was  from R. 
Vllella  (Hospital  Chnlc i  Provincial, Barcelona,  Spain);  CD48 
mAb 5-4.8 was  from M.S.  Sandnn (Austin  Research  Institute, 
Heidelberg, Austraha);  CD43  mAb L10  was from E.  Remold- 
O'Donnell (Harvard Medical School,  Boston, MA); CD40 mAb 
G28-5 was from J.A. Ledbetter (Bristol-Meyers  Squibb Pharma- 
ceutical Research Institute, Seattle, WA); CD58 mAb 1A10 was 
from S.  Meuer (German Cancer Research  Center, He,delberg, 
Germany); CD59  mAb P282  was  from A.  Bernard  (INSER.M 
Unite 29, Pans, France); CD8 mAb Campath8c was from G. Hale 
(University  of Cambridge,  UK); and MHC  class I mAb Q1/28 
was from S.  Ferrone (NY Medical College,  Valhalla, NY)  The 
CD3 mAb OKT-3 was purchased  from Ortho Diagnostics  Sys- 
tems  Inc.  (Rantan,  NJ).  CD28  mAb  Leu28  and  CD56  mAb 
Leu 19 were obtained from Becton Dickmson & Co. (San  Jose, CA), 
and CD80 mAb BB-1  was  from Serotec  Ltd.  (Oxford,  UK). 
The  CD29  mAb K20 was  from Immunotech S.A.  (Marseille, 
France). CD54 mAb RR1/1 was from Bender AG (Vienna, Aus- 
tria).  CD86  mAb IT2.2 was purchased from PharMingen (San 
Diego, CA), and CD19 mAb HD37 was from Behring. 
Fab fragments  of mAb 6F5  (CD43)  were prepared  usmg pa- 
pain and the  recommended protocols from the Avid Chrom  TM 
F(ab) kit (Bioprobe International, Inc., Tustm, CA).  The prepa- 
ration was further purified by affinity chromatography with pro- 
tein A and size fractionatlon with FPLC superdex TM 200 gel filtra- 
tion  (Pharmacia,  Uppsala,  Sweden).  Purity was  checked  using 
SDS-PAGE followed by silver staining. 
Cell Lines.  The following cell lines were used in this study: 
EBV-LCL HB654-SN, XX224  (kindly provided by H. Jungfer 
and U. Weidle, Boehringer-Mannheim, Penzberg,  Germany), and 
OTMA (our laboratory)  and the myeloid cell 1,nes RC-2a and 
HL-60 (American Type Culture Collection). 
Cell Preparation.  PBMC were isolated from heparinized whole 
blood of normal healthy donors by standard density gradient cen- 
trifugation with Ficoll-Paque (Pharmacia).  Subsequently, mono- 
cytes, T  cells, B cells, and NK cells were separated by magnetic 
sorting using the MACS technique (Mlltenyi Biotec GmbH, Ber- 
gisch  Gladbach,  Germany) as previously described  (25). Mono- 
cytes  were  isolated  by  positive  selection  with  CD14  mAbs 
VIM13  and MEM18.  Purified T  cells were  obtained through 
negative depletion of CD 11b, CD 14, CD 16, CD 19, CD33, and 
MHC class II-posinve cells with the respective mAbs. B cells and 
NK cells were isolated by posinve selectmn with CD19 mAb and an 
NK cell isolation kit (Milteny,),  respectively. 
The CD4 + and CD8 + T cell subpopulatlons were further iso- 
lated from purified T cells with CD8 mAb VIT8 and CD4 mAb 
VIT4, respectively,  by negative selection with sheep anti-mouse 
IgG Dynabeads (Dynal. Hamburg, Germany). Purity of each sub- 
population was regularly >90%. Monoclonal TCR-~,/8  + T cells 
were  obtained from the  mononuclear cell fraction of a patient 
with T cell leukemia. The mononuclear cell fraction of this patient 
consisted of 95% T cells (CD3+),  of which 93% were TCR-y/8  + 
and 2% were TCR-ot/~  +. Polymorphonuclear  granulocytes were 
prepared  as previously described  (26). Sheep  erythrocytes  were 
purchased  form Immuno AG (Vienna, Austria). 
Generation of AIonocyte-derived (rod) DC.  md-DC were gener- 
ated according to Sallusto and Lanzavecchia (27) by cultunng pu- 
rified blood monocytes for 8 d with a combination ofrhGM-CSF 
(50 ng/1-ul) and rhIL-4 (1,000 U/ml) followed by rhTNF-a (50 
U/re.l) and GM-CSF (50 ng/ml) treatment for 24 h. 
Immunofluorescence Staining Procedures.  For membrane staining, 
(107/ml)  cells were incubated for 15 min at 0-4°C with conju- 
gated  (FITC or PE)  or unconjugated mAb. For stainmgs using 
unconjugated mAbs, FITC-conjugated F(ab')2 fragments of sheep 
anti-mouse Ig antibodies (An der Grub) were used as a second- 
step reagent as described previously (26). 
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Figure  1.  Spontaneous  T  cell  conjugate  formanon with  APC.  (/t) 
P,  estlng PB  T  cells  comcubated with  md-DC  without  cenmfugatlon. 
Clusters  at 37°C with formation of large aggregates within 2 h  (a and c). 
In contrast,  freshly isolated  PB monocytes from the same donor do not 
interact with resnng T  cells (c and d, arrows  mn&cate monocytes)  At 4°C, 
T  cells fomled typical  rosettes  with md-DC  (e)  or B-LCL  HB654-SN 
cells  (jr). (B)  Comparison  of T  cell  rosetting capacity  of different he- 
mopoletic cells at 4°C.  Results show mean values  +- SD of tbur experi- 
ments. 
How Cytometry.  Flow cytomemc  analysis was performed us- 
mga  FACScan  ® flow cytometer (Becton Dickinson lmmunocy- 
tometry Systems, San Jose, CA). 
Antigen Loading of Dynabeads.  2  ×  107  sheep  anti-mouse 
IgG--coated  Dynabeads  of 4.5-p~m  diameter  were  labeled  with 
CD58 mAb  1A10 (50 ~g/ml) at 4°C for 2 h. The mAb is against 
an epitope  on CD58  that is not involved in CD2  binding (28). 
After washing twice in PBS, the beads were incubated with irrel- 
evant  mouse  IgG1  mAb  VIAP  (100  Ixg/ml)  to  block  the  free 
anti-mouse binding site and washed twice.  Then,  rhCD58  pro- 
tein  (kindly provided by U.  Moebius and S.C.  Meuer,  German 
Cancer  Research  Center,  Heidelberg,  Germany)  was  added  to 
the  beads  and  incubated for  2  h  at  4°C.  Afterwards,  the  beads 
were  washed  two  times.  CD58  molecule  loading  of beads  was 
controlled  by  stalnmg  them  with  CD58  mAb  TS2/9,  directed 
agamst an epitope on CD58 distinct from the capture mAb 1A10. 
Coating of MHC-I  to  Dynabeads  was  done  as  described for 
CD58  beads by using the anti-MHC-I mAb Q1/28  (29) as cap- 
ture antibody. After blocking residual free anti-mouse IgG bind- 
ing sites on beads with irrelevant IgG1  mAb VIAP, MHC  class  I 
molecules from  supernatants of densely growmg LCLs  (HB654- 
SN,  OTMA, XX224) were bound. 2  X  107 mAb Q1/28-coated 
dynabeads were incubated for this purpose with 50 ml of an indi- 
vidual cell culture supernatant and gently shaken for 3  h  at 4°C. 
After three washings, the loading of beads with MHC-I  was as- 
sessed by stalnmg with FITC-labeled anti-l~2m mAb BBM.1  and 
flow cytometnc analysis.  Clear reactivity of anti-~2m mAb BBM. 1 
with all beads demonstrated effective labeling with MHC-I.  Neg- 
anve  control  staining with  mAb  6F5  (CD43,  IgG1)  ascertained 
that all anti-mouse  IgG binding sites of the beads were blocked 
and that CD43 molecules were absent (data not shown). 
Dynabeads  coated with free  MHC-I  oL  chains were  prepared 
using mAb  LA-45  as  a  capture  antibody.  This mAb  specifically 
recognizes free, not ~2m associated MHC-I R-chains (30). 
Heterotypic Adhesion Assay (Rosette Formation Assay).  The  het- 
eroadhesion experiments were performed as previously described 
(31).  APC  were  stained  with  the  vital  cell  dye  calceln-AM 
(Molecular  Probes,  Inc.,  Eugene,  OR)  at  37°C  for  5  min  and 
washed  twice.  Subsequently,  100-pA  ahquots  of APC  (106/ml) 
and T  cells (107/ml) were mixed in silicone-coated tubes (Becton 
Dickinson &  Co.)  and incubated without prior centrifugation for 
up  to  3  h  at 4°C  and 37°C,  respectively.  Heterotypic  cell adhe- 
sion of APe  and T  cells was analyzed every 30 mm using a fluo- 
resence microscope  (Leitz,  Anstoplan, Jena,  Germany).  By enu- 
merating  100  fluorescence-labeled APC,  heteroadhesion  events 
were  regarded  as  positive  (rosette)  when  at  least  three  T  cells 
(nonfluorescent) adhered to  a  single APC.  In some  experiments 
NK  cells,  B  cells,  monocytes,  granulocytes,  or  human  erythro- 
cytes were used instead ofT  cells. 
SP,  BC, rhCD58-coated beads, or MHC-I-coated beads bind- 
ing to T  ceils were analyzed by staining the T  cells (106/ml) with 
calcein-AM and subsequent addition of a 20-fold excess of SRBC 
or a 10-fold excess of beads. Without centnfugation, the mixtures 
were  Incubated for 2  h  at 4°C,  and rosette formation between 
T  cells and SRBC or beads was analyzed as described above. 
Evaluation of Sialic Acid Ceil Surface Density.  Cell  surface-associ- 
ated sialic acid was released from freshly isolated PB monocytes or 
md-DC  (5  ×  106  )  from  the  same  donors  with  V.  cholerae 
neurammldase treatment. The amount of siahc acid in the super- 
natants was then determined using the thiobarbitnric acid assay as 
described by Warren (32). As a reference standard, we used pure 
neuramimc acid from sheep submaxtllary glands  (Sigma Chemie 
GmbH). 
The  amount  of releasable cell surface  sialic acid for both cell 
types  was  related  to  cell surface  area.  For this purpose,  cell size 
was  measured  with  a  cytometer  (Multisizer  II;  Coulter,  Luton, 
U.K.),  and the minimal surface area was  calculated from cell di- 
ameter. Given the villous surface structure and numerous projec- 
tions of DC,  this method underestimates the surface area of md- 
DC m  relation to the surface area of freshly isolated monocytes. 
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HB654-SN cells cultured with  Rosette formation 
T  cells  + 
CB T  cells  + 
B  cells 
NK cells 
Monocytes 
Granulocytes 
Erythrocytes 
Idenncal results were obtained in two independent experiments. 
+  =  I>40% of HB654 cells in rosettes;  -  =  <5% of HB654 cells m 
rosettes. 
Table 2.  T  Cell Rosette Formation  Represents  an Active Process 
T  cell rosette 
formation with 
HB654-SN cells 
T  cell rosette 
formation with  Preincubation of 
HB654-  HB654- 
Agent added  md-DC  SN cells  T  cells  SN cells 
cytochalasin B  (5 Ixg/ml)  -  -  -  + 
NaF (30 mM)  -  -  -  + 
formaldehyde (1%)  .... 
EDTA (10 mM)  +  +  +  + 
Medium control  +  +  +  + 
Results 
Spontaneous  T  Cell  Conjugate  Formation  Is  a  Selective  Pro- 
cess.  For  the  assessment  of spontaneous  T  cell  conjugate 
formation,  freshly  isolated  peripheral  blood  (PB)  T  cells 
were  coincubated  without  centrifugation  with  a  panel  of 
various  types  of hemopoietic  cells.  The. binding of T  cells 
or aggregate formation was microscopically evaluated. 
Upon  coincubation for 2  h  at 37°C,  T  cells formed large 
aggregates  with  md-DC  (Fig.  1  A,  a  and  c).  Variable  de- 
grees  of aggregate  formation were  also  observed  with  the 
EBV-LCL  HB654-SN,  OTMA,  and  XX224.  No  aggre- 
Idenncal results were obtained in three independent experiments. 
-,  <5% APC m rosettes;  +, I>30% APC in rosettes. 
gate formation whatsoever was  observed with the myeloid 
cell lines HL-60  and RC-2a  or with purified PB B  cells or 
monocytes  (Fig.  1 A,  b and d). 
At  the  single-cell  level,  more  clearly  visible and  distin- 
guishable was  heterotypic  adhesion  at 4°C.  Upon  coincu- 
bation  at  4°C,  T  cells  formed  typical  rosettes  with  single 
md-DC  (Fig.  1 A, e) and LCL HB654-SN  cells (Fig.  1 A,f). 
An  average  of  24  -+  7%  of  md-DC  and  46  +  9%  of 
Table 3.  Antibody Inhibition  Study on HB654-SN/T  Cell Rosette Formation 
mAbs against APC antigens  Rosette formation  mAbs against T  cell anngens  Rosette formation 
5D7  CD5  + +  TS2/18  CD2  + 
G28-5  CD40  +  +  VIT3  CD3  + + 
L10  CD43  + +  VIT4  CD4  + + 
6B6  CD44  +  +  5D7  CD5  + + 
VIT200  CD45  + +  VIT8  CD8  + + 
5-4.8  CD48  + +  Campath8c  CD8  +  + 
RR1/1  CD54  + +  TS1/22  CD1 la  + + 
TS2/9  CD58  -  TS1/18  CD18  + + 
P282  CD59  + +  A24  CD26  + + 
BB1  CD80  +*  VIT14  CD27  + + 
IT2.2  CD86  + +  Leu28  CD28  +* 
VIM3c  CD97  + +  K20  CD29  + + 
W6A}2  MHC-I  -  6F5  CD43  + + 
BBM. 1  [~21"n  --  6B6  CD44  + + 
L243  MHC-II  + +  UCHL-1  CD45RO  + + 
AAA1  M6  + +  TA9  CD99  +  + 
Indenucal results were obtained m three independent experiments. 
+ +  =  I>40% LCL-HB654-SN cells m rosettes (medium control was 50 ±  6% rosettes);  +  =  <20% LCL-HB654-SN cells in rosettes;  -  =  < 10% 
LCL-HB654-SN cells m rosettes. 
*  Transient inhibition. 
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Figure 2.  Inhlbmon  of rosette formatmn with mAbs against MHC-I 
on APC. Preincubatmn of HB654-SN  cells, but not T cells, w~th antl- 
MHC-I mAb W6/32 and mAb BBM.1 (132m) inhibits T cell rosette for- 
matron,  whereas premcubatmn  with  MHC-I  mAb  Q1/28  of rather 
HB654-SN or T cells had no effect. Addmon of mAb W6/32 or TS2/9 
(CD58) was also inhibitory for md-DC-T cell interaction. Results m&- 
cate mean values -+ SD of three experiments 
HB654-SN  cells bound  three  or more  T  cells (Fig.  1  B). 
Rosette  formation,  albeit weaker,  was  also  observed with 
LCL  XX224  and  OTMA  cells, but  not  with  PB  B  cells, 
monocytes,  or  the  myeloid cell lines  HL-60  and  RC-2a 
(Fig. 1 /3). 
Spontaneous conjugate formation with HB654-SN  cells 
seems to be a selective feature ofT cells. As shown in Table 1, 
both  PB  and  cord  blood  (CB)  T  cells  strongly  bound, 
whereas  PB  B  cells,  NK  cells,  monocytes,  granulocytes, 
and red blood cells showed no rosette formation. 
T  cell rosette formation at 4°C with md-DC and HB654- 
SN cells seems further to represent an active process (Table 
2). Addition of the metabolic inhibitor NaF or cytochalasin 
B  to the coculture or pretreatment of T  cells with NaF or 
cytochalasin B  prevented rosette formation. Fixation of ei- 
ther cell type with formaldehyde before coincubation abol- 
ished conjugate  formation.  In  contrast,  chelation of diva- 
lent  cations  with  EDTA  had  no  inhibitory  effect.  T  cell 
adhesion to md-DC and HB654-SN  cells thus seems to re- 
quire  metabolic  energy  and  an  intact  cytoskeleton, but  is 
obviously not dependent on extracellular divalent cations. 
MHC  Class  I Molecules Are Involved in APC-T  Cell Inter- 
action.  To  elucidate which  molecules might be involved 
in  the  observed rosette  formation  of resting T  cells with 
md-DC  and LCL HB654-SN  cells, we selected a panel of 
mAbs against molecules expressed on md-DC  as well as on 
HB654-SN  cells.  Also  included  was  a  panel  of  mAbs 
against T  cell antigens. All were  tested for their ability to 
inhibit rosette formation of T  cells with  the  "model-cell" 
HB654-SN. 
As shown  in Table 3,  CD58  mAb TS2/9  was the most 
efficient  inhibitor  among  the  analyzed  mAbs  against  cell 
surface  molecules  on  the  APC  side.  Inhibition,  although 
only within  the  first  90  min  of incubation,  was  also  ob- 
served with the CD80  (t37) mAb BB-1. mAbs against other 
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CD8  + T cells 
clonal TCRy/o  ~+ I 
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(CD4"/CDS") 
medium control 
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medium control 
+W6/32 (MHC-I  I 
medium control 
+W6/32 (MHC-I) 
medium control 
+W6/32 (MHC-I) I 
0  10  20  30 
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40 
Figure 3.  MHC-I-dependent APC-T  cell interaction does not require 
CD8/TCR-oe/[3  molecules on the T  cell side. MHC-I-dependent rosette 
fomlanon  of T  cells with  HB654-SN  cells was  observed with purified 
CD4+CD8  as well as w]th  CD8+CD4 -  or unfracnoned  T  cells. This 
formanon also occurred with CD4-CD8  clonal 3~/8  T  cells from a pa- 
nent with T  cell leukemia. Results show mean values of two experiments. 
molecules on the APC side were not inhibitory. At the T  cell 
side, this inhibition pattern was reflected by a clear-cut in- 
hibitory effect of CD2  mAb TS2/18  and moderate inhibi- 
tion with  CD28  mAb Leu28.  mAbs against other promi- 
nent T  cell antigens were not inhibitory (Table 3). 
Suprisingly, very pronounced inhibition of T  cell rosette 
formation  was  also  observed with  mAb  W6/32  directed 
against  a  monomorphic  epitope  on  the  MHC-I  ot  chain 
and  with  mAb BBM. 1  directed against ]32m. Addition of 
mAb Q1/28 directed against a different monomorphic epi- 
tope of MHC-I  ot chain than mAb W6/32  (29) or purified 
~2  m  molecules (data not shown)  had no  inhibitory effect. 
Subsequently  performed  separate  preincubation  experi- 
ments  of HB654-SN  or T  cells revealed that both  mAbs 
(W6/32  and  BBM.1)  mediated  inhibitory  effects  only 
when HB654-SN  cells were pretreated wtth the respective 
mAbs before setting up the rosette formation assay (Fig. 2). 
MHC-I  molecules also  seem  to  be  critical for md-DC/T 
cell rosette formation. T  cell binding to md-DC can also be 
efficiently inhibited with MHC-I  mAb W6/32  (Fig. 2). 
Search for Candidate  Counterreceptors on  T  Cells for MHC-I. 
The  two  prototype MHC-I  counterreceptors  on  T  cells, 
the  monomorphic  receptor structure  CD8  and  the  clonal 
MHC-I/peptide receptor structure TCR.-ot/[3  (33-35)  do 
not seem to be responsible for the observed adhesion phe- 
nomena. 
Purified CD8  CD4 + T  cells bind to the same extent to 
HB654-SN  cells as do  CD8+CD4 -  cells, and  adhesion is 
equally inhibitable by  mAb  W6/32  (Fig.  3).  rnAb  Cam- 
path8c, shown before to inhibit MHC-I-CD8  interactions 
(34),  has no  inhibitory effect in our test system (Table 3). 
For TCR-0~/13  to be responsible, one would have to pos- 
tulate that up to 50% of the added PB T  cells recognize an- 
tigenic epitopes presented by md-DC  or HB654-SN  cells, 
respectively. This is rather unlikely. In addition, we could 
demonstrate  that  a  clonal population  of TCR-'y/B ÷  cells 
(CD4-CD8-)  from a patient with T  cell leukemia also av- 
idly binds to HB654-SN cells (Fig. 3). 
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Figure 4.  Acnvanon of the CD2 adhesion pathway upon hganon of 
CD43 with mAb 6F5. (/t) Engagement of CD43 on T cells with mAb 
6F5 reduces CD2-dependent sheep erythrocyte rosettlng. (B) Engage- 
ment of CD43 on T cells with mAb 6F5 tnggers  binding ofrhCD58 pro- 
tern-coated beads In both expenmental  settings, the T cells were colncu- 
bated with targets at 4°C in the presence of the m&cated mAhs or NaF 
(30 mM) without cenmfugatlon. Results show mean values +  SD of 
three experiments  for each con&tlon. 
Other as yet undefined MHC-I ligands on T  cells must, 
therefore, be considered. They could be classical  adhesion 
molecules, which  directly mediate  T  cell binding and/or 
represent signaling structures that, upon ligation, transactl- 
vate  heterologous  adhesion  molecules.  To  us,  the  latter 
possibility appeared more likely. Such a mechanism could, 
for instance, induce enhanced adhesiveness of the T  cell- 
specific receptor structure CD2,  shown above to be criti- 
cally involved in spontaneous T  cell conjugate fomlation in 
our test conditions (Table 3).  We therefore  screened for 
T  cell surface  molecules that  are  able  to  transactivate the 
adhesiveness of CD2 under our test conditions at 4°C. 
CD43 Ligation  Transactivates CD2.  As a  system for the 
detection of potential CD2 avidity upregulating effects,  we 
used rosette formation oft  cells with SRBC under subop- 
timal conditions (no cocentrifugation) and T  cell binding 
of rhCD58-coated beads.  Fig.  4  summarizes the  effects  of 
various antibodies to T  cell surface antigens on the rosette- 
fbrmlng capacity of T  cells with SRBC  (A)  and rhCD58 
coated  beads  (B),  respectively.  By  far,  the  most  striking 
stimulatory effect was observed with CD43 mAb 6F5. This 
mAb clearly enhanced rosette formation with both targets. 
The effect was specific and could be inhibited with block- 
ing CD2  and CD58  mAbs.  It required metabolic energy 
8 
medium control 
+6FS-Fsb (CD43) 
+6F5 -intact 
~  I  mock 
+  +6F5-1ntact 
medium control  I 
+6FS-Fab (CD43) ! 
0 
IF 
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Figure 5.  Involvement  of CD43 on T cells m APC/T cell rosette for- 
mation Addmon of Fab fragments of CD43 mAb 6F5 inhibited rosette 
formation ofT cells with HB654-SN cells, which do not express the 6F5- 
defined epltope. Inhlbinon was  also shown with md-DC.  Intact 6F5 
mAb, however, enhanced APC/T cell rosette formation and was capable 
of reconstituting rosette formation after inhibition w]th MHC-I  mAb 
W6/32. Results represent mean values -4- SD of three expenments. 
and did not occur in the presence of NaF. Engagement of 
CD43  and, in particular, of the CD43 epitope recognized 
by mAb 6F5 thus transactivates the adhesiveness of CD2. 
CD43 Molecules on  T  Cells Are Involved in  T  Cell Conju- 
gate Formation.  To evaluate whether CD43 molecules on 
T  cells  are  indeed involved in the  observed spontaneous 
adhesion ofT cells to HB654-SN cells or md-DC, we ana- 
lyzed the  effects  of intact CD43  mAb 6F5  and Fab frag- 
ments of this mAb on T  cell rosette formation. As can be 
seen from Fig. 5, the two mAb preparations gave discrepant 
effects.  Fab fragments strongly inhibited rosette formation 
of T  cells with HB654-SN cells or md-DC.  Inhibition of 
APC-T  cell  interactions with  Fab  fragments  of 6F5  and 
W6/32 rnAb was found at 4°C as well as at 37°C (data not 
shown). Because HB654-SN cells do not express the 6F5- 
defined  epitope,  Fab  fragments  of mAb  6F5  seemed  to 
compete  at  the  T  cell  side  with  an  adhesion-promoting 
ligand on APC. In contrast, intact 6F5 enhanced T  cell ro- 
sette formation and seemed to imitate signaling properties 
of such a presumed ligand. IfMHC-I were this ligand, then 
proadhesive  signals  induced  by  intact  CD43  mAb  6F5 
should  reverse  anti-MHC-I mAb  W6/32-caused inhibi- 
tion  of T  cell  rosette  formation.  As  can  be  further  seen 
from  Fig.  5,  this was  indeed observed.  Reconstituted ro- 
sette formation was then completely inhibited with CD58 
mAb TS2/9 (data not shown). 
Engagemetlt of CD2 Transactivates CD43 and Induces MHC-I 
Binding.  The  results  obtained  so  far  demonstrate  that 
CD43 on T  cells and MHC-I on md-DC and HB654-SN 
cells play critical roles in spontaneous T  cell conjugate for- 
mation.  They  further  suggest,  but  do  not  yet  formally 
prove,  that  these  two  molecules physically interact  with 
each other in this process. We therefore attempted to dem- 
onstrate more directly MHC-I binding to CD43 on T  cells. 
For  this  purpose,  we  coincubated purified  T  cells  with 
MHC-I-coated beads and checked for MHC-I bead bind- 
ing to T  cells. As can be seen from Fig. 6, only insignificant 
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Figure  6.  Binding studies  of 
MHC-I  protein-coated  Dyna 
beads  to  T  cells  (A)  MHC-I 
protem-labeled  beads  showed 
only  little  and  unspecific bind- 
ing to resting T  cells  However, 
upon  addition  of  a  stimulatory 
CD2  mAb  pair  (VIT13,  TS2/ 
18),  ~30% of the T  cells bound 
at least three heads. Binding to T 
cells could be  specifically inhib- 
ited with mAb W6/32  and  Fab 
fragments of mAb  6F5  (CD43), 
but  not  with  CD8  mAb  Cam- 
path8c.  (B) Illustration of the low 
frequency  of  MHC-I-loaded 
beads  bound  to  T  cells and  the 
appearance of bead rosettlng with 
T  cells activated via CD2. 
and nonspecific it~Jbited binding of beads can be observed. 
Affinity for MHC-I, if it exists at all, thus seems to be too 
low to be detectable in this test system. 
Having observed that ligation of CD43 upregulates CD2 
adhesiveness, we postulated that engagement of CD2 might 
crosswise  activate  CD43  and  induce  detectable  MHC-I 
binding. Results presented in Fig. 6 demonstrate that this is 
indeed the case. Engagement ofT cell CD2 molecules with 
the  stimulatory CD2  pair mAb TS2/18  plus mAb VIT13 
(36)  induced  significant binding  of MHC-I-coated beads 
(33  +  9% of T  cells bound three or more MHC-I-coated 
beads).  Binding was found to be specific, because it is in- 
hibited by anti-MHC-I mAb W6/32.  It seemed to involve 
CD43  on T  cells,  because it was also  significantly reduced 
by Fab fragments ofCD43 mAb 6F5 but not by CD8 mAb 
CampathSc.  Binding  was  not  only  obtained  with  beads 
coated with MHC-I from culture supernatants of HB654- 
SN  cells,  but  also  with  MHC-I  from  two  other  LCLs 
(OTMA, XX224)  (data not shown).  In all instances,  CD2 
triggered binding of T  cells  to MHC-I beads was reduced 
to  background  in  the  presence  of NaF,  indicating  energy 
dependence.  CD2  mAbs  were  required  for  induction  of 
binding  of MHC-I  beads.  Other  mouse  mAbs  (W6/32, 
6F5)  had no such effect. Intact MHC-I ix chain-132m het- 
erodimers  were  required  for  binding  to  occur.  Beads 
coated with free MHC-I ix chains did not bind (Fig.  6 A). 
Given the evidence that CD43 molecules on T  cells can 
be induced  to physically bind MHC-I, we postulated that 
this "adhesion molecule pair" can also per se mediate T  cell 
binding to HB654-SN cells.  To visualize such binding, we 
first  had  to  "knock  out"  the  normally  occurring  CD2/ 
CD58 adhesion pathway by adding inhibitory CD58 mAb 
TS2/9 to our T  cell/HB654-SN cell coculture system. This 
completely prevented spontaneous T  cell conjugate forma- 
tion.  However, when subsequently adding the stimulatory 
CD2  mAb pair,  significant rosette formation could be re- 
1775  St6cld  et al. 
observed (Fig.  7).  This CD2 m_Ab-induced conjugate for- 
mation in the presence of CD58 mAb TS2/9 could be sig- 
nificantly inhibited by CD43 mAb 6F5  Fab fragments and 
by  intact  MHC-I  mAb  W6/32,  but  not  by  CD5  mAb 
5D7. The direct involvement of CD43 molecules on T  cells 
in  this  type  of T  cell conjugate  formation is  further sup- 
ported  by  our  finding  that  O-SGP  treatment  of T  cells, 
leading  to  CD43  molecule  cleavage  (37),  prevents  CD2 
mAb pair-inducible T  cell rosette formation (Fig.  7). 
Discussion 
Several studies have shown that freshly isolated resting 
T  cells are extremely selective in their capacity to bind and 
medium control ~ 
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+CD2-mAb pair+ W6/32 (MHC-I) 
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Figure  7.  MHC-]  and CD43 function as adhesion molecules in APC-T 
cell interaction. Rosette formation of T  cells with HB654-SN  cells was 
blocked with CD58 mAb TS2/9 and subsequently restored through sig- 
naling via CD2. APC-T cell interaction under th]s con&tion seems to be 
mediated via MHC-I-CD43 interactions, because it ts lnhibated with the 
respective mAbs W6/32 and 6F5 (Fab  fragments)  Reconstitution of ro- 
sette formation via CD2  was not  observed when  CD43  was removed 
from T  cells upon O-SGP treatment  Results indtcate mean values +  SD 
of three experiments. form  stable  conjugates  with  other  cells.  The  two  most 
prominent cell types to which resting T  cells were shown 
to spontaneously adhere are DC (1-4,  10,  13,  23,  24)  and 
activated B blasts  (3, 6,  12,  19-21). 
In this  study,  we  addressed  the  question  which  surface 
molecules, in addition to the already known adhesion mol- 
ecule pairs such as LFA-1/ICAM-1,2,3,  CD2/LFA-3,  and 
CD28/B7  (4,  13,  21,  23,  24)  might play a critical role in 
such spontaneous T  cell conjugate formation with DC and 
activated B blasts.  We used for this purpose DC generated 
from mouocytes (md-DC) and an EBV-LCL (HB654-SN) 
observed to be particularly efficient in T  cell binding. 
To  our  surprise,  we  found  two  surface  molecules,  al- 
ready known for other reasons, to be critically involved in 
this T  cell conjugate formation process: sialomucin (CD43) 
on T  cells  and MHC-I on md-DC and HB654-SN  cells, 
respectively. T  cell conjugate formation could be strongly 
inhibited  by  either  preincubatlng  T  cells  with  Fab  frag- 
ments of CD43  mAb 6F5  or by preincubating APC  (md- 
DC, HB654-SN) with MHC-1 mAb W6/32 or [32m mAb 
BBM. 1. 
The  mode  of action  of  CD43  molecules  on  T  cells 
turned out to be particularly interesting in this context. Us- 
ing  intact  bivalent  CD43  mAb  6F5  instead  of Fab  frag- 
ments, we could demonstrate that ligation of CD43, under 
cross-linking conditions with intact mAb, enhances rather 
than inhibits T  cell binding. This, together with the obser- 
vation that Fab fragments inhibit, suggests that the molecu- 
lar region  of CD43  recognized by mAb 6F5  represents a 
signal transducing recognition site for a stlmulatory ligand 
on the  investigated target cells.  Blockage of this  site with 
Fab fragments obviously inhibits ligand interaction.  Cross- 
linkage  of this  site  on  CD43  with  intact  mAb  seems  to 
mimic ligand interaction and to induce a signaling cascade, 
leading to enhanced T  cell adhesiveness. 
Signaling via CD43, upon ligation with specific mAbs, is 
a well-documented phenomenon. It involves phosphoryla- 
tion  of a  specific  protein  substrate  (38),  promotes  T  cell 
proliferation with particular mAbs (39,  40), and, at 37°C, is 
regularly  accompanied  by  enhanced  cellular  adhesiveness 
and  homoaggregate  formation  (41-43).  CD43-mediated 
[31- and [32-integnn activation seems to play a predominant, 
although perhaps not an exclusive, role in all adhesion phe- 
nomena described so far (41).  However, such an involve- 
ment of integrins is quite  unlikely in our assay system. As 
observed by us,  CD43-regulated  T  cell  adhesiveness  also 
occurred at 4°C  and was independent  of divalent cations. 
Cellular signaling at 4°C is not unique and has been shown 
betbre  for several receptor structures  (44,  45).  However, 
integnn-mediated  adhesion  is  known  to  be  temperature 
sensitive and divalent cation dependent (5).  Other temper- 
ature-insensitive and divalent cation-independent adhesion 
molecule systems must, therefore, be taken into  consider- 
ation. 
The  best  known  T  cell  adhesion  molecule  fulfulling 
these requirements is certainly CD2 (5). We therefore eval- 
uated the influence ofCD43 ligation on CD2 function and 
could indeed show that cross-linkage of CD43 with intact 
CD43  mAb  6F5  induces  significantly  upregulated  adhe- 
siveness of CD2 for its ligand LFA-3 (CD58). The adhesive 
state of CD2 thus seems to be under regulatory control of 
the T  cell surface molecule CD43. 
Given the evidence for a signal-receiving and -transmit- 
ting function of CD43,  the question of course arises,  what 
is the nature of the presumed CD43 ligand on target cells? 
Is it perhaps MHC-I, shown by us to play a critical role on 
the target cell side? The first evidence in this direction was 
our observation that the anti-MHC-I mAb W6/32-caused 
inhibition ofT cell conjugate formation can be reversed by 
T  cell CD43  ligation with intact CD43  mAb 6F5.  How- 
ever, attempts to  demonstrate more directly binding with 
MHC-I-coated beads coincubated with resting CD43 + T 
cells were initially unsuccessful. 
Having  seen  before  a  functional  linkage  between  the 
two T  cell surface molecules CD43  and  CD2,  we postu- 
lated  that  signaling  also  occurs  in  the  reverse  direction, 
leading to upregulated ligand binding of CD43 upon liga- 
tion of CD2. Signaling via CD2 is also a well-documented 
phenomenon (36,  46) and has been shown before to occur 
at 4°C (45). Regulated adhesiveness of CD43 has not as yet 
been reported.  However,  hyperphosphorylation of CD43 
upon T  cell activation was described (47).  Using a stimula- 
tory pair of CD2 n-tAbs, we could indeed demonstrate that 
ligation of CD2 on T  cells induces CD43-dependent bind- 
ing  of MHC-I-coated  beads  and  MHC-class  I-positive 
HB654-SN cells, respectively. 
Taken together, these findings suggest that CD43 mole- 
cules on T  cells can, under certain conditions,  directly in- 
teract  with  MHC-I  on  other  cells.  Such  interaction  and 
cross-linkage of CD43 on T  cells subsequently induces up- 
regulated CD2 adhesiveness for CD58.  Crosswise engage- 
ment of CD2 with its ligands seems to activate CD43 and 
to upregulate its avidity for MHC-I. 
Such  a  scenario  does  not  occur,  however,  between  T 
cells  and  every  other  MHC-I-  and/or  CD58-expresslng 
cell type.  Several MHC-I+LFA-3 + cells  studied by us did 
not  form  stable  conjugates  with  freshly  isolated  T  cells. 
Among them are the myeloid cell lines HL-60 and RC-2a. 
PB monocytes and B  cells,  which express MHC-I and are 
at least weakly CD58 +, also  do not spontaneously form T 
cell conjugates. 
Additional criteria must obviously be fulfilled in order to 
allow the described mteractions between CD43 and MHC-I 
and  the  consequent  transregulations  between  CD43  and 
CD2 to be initiated.  One such criterion might be reduced 
charge-based  repulsion  between  T  cells  and  target  cells 
(48). The degree of cell surface molecule sialylation is a major 
denominator of the  overall negative surface charge of hu- 
man leukocytes  (49,  50)  and  represents  an  important  pa- 
rameter for cell-cell contact (51-53). 
The leukocyte-specific surface molecule leukosialin (CD43) 
represents  one  of the  most highly sialylated glycoproteins 
known on human hemopoietlc cells  (50,  54--56).  From its 
structure  one  can predict  that it has a  rod-like  configura- 
tion,  which protrudes much further from the surface than 
most other glycoproteins (56).  As a result of this extended 
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likely to contribute significantly to the overall negative sur- 
face charge of human leukocytes.  As such it might repre- 
sent a repulsion  molecule that prevents hemopoietic cells, 
including  T  cells,  to  firmly  associate  with  other  cells,  in 
particular,  with other negatively charged cells.  Experimen- 
tal evidence for that has indeed been presented (53, 57, 58). 
In  the  case  of prominent  charge-based  repulsion  be- 
tween a T  cell and an adjacent cell,  CD43 molecules on T 
cells  should  not  come  into  close  and  prolonged  contact 
with potential hgand molecules on the opposing cell. MHC-I 
on a highly negatively charged cell should, thus, be unable 
to sufficiently engage and polymerize CD43 molecules on 
T  cells to induce effective signaling. 
In contrast,  reduction  of net  cell surface  charge  should 
allow and promote interaction.  Such charge reduction can, 
for Instance, be achieved by enzymatic removal of cell sur- 
face sialic  acid residues. Indeed, neuraminidase treatment of 
different  cell  types such  as  B  ceils  (19,  20,  59,  60),  mac- 
rophages  (22),  erythrocytes  (51),  or  ICAM-l-transfected 
HeLa cells  (53)  has been shown  to promote  T  cell adhe- 
sion. Reduced or altered sialylation might also be involved 
in the preferential binding of resting T  cells to DC and ac- 
tivated B cells.  Both cell types were shown to constitutively 
express hyposialylated cell surface molecules (20, 60--62). 
The  degree  or  nature  of target  cell  surface  sialylation 
seems  also  to  play  a  role  in  our  model  system,  md-DC, 
which efficiently bind T  cells, show a clearly lower density 
of sialic  acid on their  surface  than  freshly isolated,  non-T 
cell-binding  monocytes  (0.9  vs.  1.6  fM/mm  2,  respec- 
tively). The B-LCL found to be superior in T  cell binding 
(HB654-SN cells)  is constitutively hyposialylated and lacks, 
for instance,  the sialylation-dependent  CD43  epitope  recog- 
nized by mAb 6F5  (Majdic,  O.,  unpublished  observation). 
The other B-LCLs tested  (XX224  and OTMA),  normally 
sialylated,  showed only moderate spontaneous T  cell binding 
before  and  strongly  upregnlated  binding  after  neuranfini- 
dase treatment  (OTMA from 7  -+ 4% to 26  +  9%, XX224 
from 13 +  6% to 54 +  7%). 
Taken together, our findings show that certain cell types, 
in  particular,  potent  accessory  cells  such  as  md-DC  and 
lymphoblastmd B  cells,  have the  capacity to interact  with 
resting T  cells via surface  molecules  MHC-I  and  CD43, 
respectively.  We have shown this interaction  to occur in 
a  model  system  and  have  analyzed  its  functional  conse- 
quences.  The conditions we had to use to clearly visualize 
the individual steps in this process are certainly not physio- 
logical.  We  nevertheless  believe  that  the  demonstrated 
CD43/MHC-I  adhesion pathway and its functional inter- 
action with the well-established CD2/LFA-3 system might 
also under in vivo conditions play a potentially important 
role in T  cell activation and/or mediation of effector func- 
tions. 
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